BACKGROUND: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. METHODS: Multiplex kits were tested on serial plasma samples obtained from six RA patients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RA patients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFalpha antibody (infliximab). RESULTS: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RA patients. CONCLUSIONS: In plasma of RA patients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFalpha, Il-9, IL-1beta, IFNgamma, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RA patients. (c) 2008 Clinical Cytometry Society.
BACKGROUND: Multiplex analysis allows measurements of a large number of analytes simultaneously in each sample. On the basis of the Luminex multiplex technology (xMAP), kits for measuring multiple cytokines and chemokines (immunomodulators) are commercially available and are useful in investigations on inflammatory diseases. This study evaluated four multiplex kits (Bio-Plex, LINCOplex, Fluorokine, and Beadlyte) that contained 27, 29, 20, and 22 analytes each, respectively, for the analysis of immunomodulators in plasma of patients with rheumatoid arthritis (RA) who underwent treatment with antibody against CD20 (rituximab), a B-cell reductive therapy. METHODS: Multiplex kits were tested on serial plasma samples obtained from six RApatients at baseline and multiple time points (3, 6, and 9 months) post-treatment with rituximab. The RApatients included in this study had previously failed therapy with disease modifying anti-arthritis drugs (DMARD) and treatment with anti-TNFalpha antibody (infliximab). RESULTS: Computer modeling and hierarchical cluster analysis of the multiplex data allowed a comparison of the performance of multiplex assay kits and revealed profiles of immunomodulators in the RApatients. CONCLUSIONS: In plasma of RApatients who appeared to have benefited from the rituximab treatment, the profile of significantly elevated immunomodulators by at least two of the three kits (BioPlex, LINCOplex, Beadlyte) is as follows: IL-12p70, Eotaxin, IL-4, TNFalpha, Il-9, IL-1beta, IFNgamma, IL-10, IL-6, and IL-13. Immunomodulator profiling by multiplex analysis may provide useful plasma biomarkers for monitoring response to B-cell reductive therapy in RApatients. (c) 2008 Clinical Cytometry Society.
Authors: Walter F Bobrowski; J Eric McDuffie; Gregg Sobocinski; Jonathan Chupka; Eric Olle; Amy Bowman; Mudher Albassam Journal: Cytokine Date: 2005-10-28 Impact factor: 3.861
Authors: Gabriele di Comite; Alessandro Marinosci; Paola Di Matteo; Angelo Manfredi; Patrizia Rovere-Querini; Elena Baldissera; Patrizia Aiello; Angelo Corti; Maria Grazia Sabbadini Journal: Ann N Y Acad Sci Date: 2006-06 Impact factor: 5.691
Authors: Robert C Gentleman; Vincent J Carey; Douglas M Bates; Ben Bolstad; Marcel Dettling; Sandrine Dudoit; Byron Ellis; Laurent Gautier; Yongchao Ge; Jeff Gentry; Kurt Hornik; Torsten Hothorn; Wolfgang Huber; Stefano Iacus; Rafael Irizarry; Friedrich Leisch; Cheng Li; Martin Maechler; Anthony J Rossini; Gunther Sawitzki; Colin Smith; Gordon Smyth; Luke Tierney; Jean Y H Yang; Jianhua Zhang Journal: Genome Biol Date: 2004-09-15 Impact factor: 13.583
Authors: Delynn M Moss; Jeffrey W Priest; Alexis Boyd; Tiffany Weinkopff; Zuzana Kucerova; Michael J Beach; Patrick J Lammie Journal: Am J Trop Med Hyg Date: 2011-08 Impact factor: 2.345
Authors: Tanya B Dorff; Bryan Goldman; Jacek K Pinski; Philip C Mack; Primo N Lara; Peter J Van Veldhuizen; David I Quinn; Nicholas J Vogelzang; Ian M Thompson; Maha H A Hussain Journal: Clin Cancer Res Date: 2010-05-18 Impact factor: 12.531
Authors: Howard S Moskowitz; William E Gooding; Sufi M Thomas; Maria L Freilino; Neil Gross; Athanassios Argiris; Jennifer R Grandis; Robert L Ferris Journal: Oral Oncol Date: 2012-06-23 Impact factor: 5.337
Authors: Jan M Hughes-Austin; Kevin D Deane; Lezlie A Derber; Jason R Kolfenbach; Gary O Zerbe; Jeremy Sokolove; Lauren J Lahey; Michael H Weisman; Jane H Buckner; Ted R Mikuls; James R O'Dell; Richard M Keating; Peter K Gregersen; William H Robinson; V Michael Holers; Jill M Norris Journal: Ann Rheum Dis Date: 2012-08-21 Impact factor: 19.103
Authors: Jukka Hintikka; Soili M Lehto; Leo Niskanen; Anne Huotari; Karl-Heinz Herzig; Heli Koivumaa-Honkanen; Kirsi Honkalampi; Sanna Sinikallio; Heimo Viinamäki Journal: BMC Public Health Date: 2009-11-12 Impact factor: 3.295